Partial
Partially Aligned
Patient Risk:
Low
Summary
Several claims match the provided label excerpts (brand/generic relationship, indications, oral administration, and broad adverse effects/monitoring). However, the AI-style claims are overly general and some are only partially supported: specifically, the ROS1 context is not fully evidenced in the supplied indication excerpt beyond stating “ALK- or ROS1-positive metastatic NSCLC,” and the claimed “targeted therapy designed to block cancer signaling from ALK/ROS1” is not directly phrased that way in the provided mechanism section. Also, monitoring guidance for “vision changes” is more specific in the label than the broad claim.
Category Scores
Accurate Statements
Xalkori is the brand name for crizotinib.
DESCRIPTION: “XALKORI (crizotinib) capsules…” and clinical sections use XALKORI for crizotinib.
Xalkori is a prescription medicine used to treat certain cancers.
INDICATIONS AND USAGE 1.1: “XALKORI is indicated for the treatment of adult patients with metastatic non-small cell lung cancer…”
Xalkori is used for non-small cell lung cancer (NSCLC) with ALK rearrangements.
INDICATIONS AND USAGE 1.1: “metastatic NSCLC whose tumors are … ALK or ROS1-positive as detected by an FDA-approved test.”
Xalkori is used for NSCLC with ROS1 rearrangements in some approved contexts described in prescribing information.
INDICATIONS AND USAGE 1.1: same sentence includes “ALK or ROS1-positive” metastatic NSCLC.
Xalkori is used to treat ALK-positive NSCLC.
INDICATIONS AND USAGE 1.1: “metastatic NSCLC whose tumors are … ALK … positive…”
Xalkori is used to treat ROS1-positive NSCLC in the approved contexts described in prescribing information.
INDICATIONS AND USAGE 1.1: includes ROS1-positive metastatic NSCLC.
Crizotinib is a kinase inhibitor.
DESCRIPTION: “Crizotinib is a kinase inhibitor.”
People taking Xalkori may experience gastrointestinal effects such as nausea, vomiting, and diarrhea.
2.6 / Table 8 shows gastrointestinal toxicity with entries for nausea, vomiting, and diarrhea (as adverse-reaction severity categories with dosage modifications).
People taking Xalkori may experience fatigue.
People taking Xalkori may experience vision changes.
5.5 Severe Visual Loss: “The most common visual symptoms were blurred vision and visual impairment.” and “Assessment of visual symptoms… is recommended monthly… Report new visual symptoms to an eye specialist.”
People taking Xalkori may experience liver enzyme elevations and other lab abnormalities.
2.6 / Table 8 includes “Hepatotoxicity” with ALT/AST elevations and bilirubin changes (as criteria for dosage modifications).
Xalkori is taken by mouth (oral dosing).
DESCRIPTION: “XALKORI capsules for oral administration…” and “oral pellets for oral administration.”
Dosing schedules and adjustments for Xalkori are described in the prescribing information.
2.6: “The recommended dosage modifications for adverse reactions…” and multiple dosage modification tables/criteria.
Dose changes for Xalkori are based on tolerance and lab results.
2.6/Table 4 (tolerability/discontinuation wording) and Table 8 criteria based on ALT/AST/bilirubin and other adverse-reaction criteria.
Unsupported Statements
Crizotinib is a targeted therapy designed to block cancer signaling from ALK.
Label mechanism section states crizotinib is an inhibitor of receptor tyrosine kinases including ALK and describes inhibition of ALK phosphorylation/signaling, but it is not explicitly framed as “targeted therapy designed to block cancer signaling from ALK.”
Crizotinib is a targeted therapy designed to block cancer signaling from ROS1.
Same issue as ALK: mechanism section supports ALK/ROS1 inhibition and phosphorylation inhibition, but does not use the specific “targeted therapy designed to block cancer signaling” phrasing.
People taking Xalkori may experience fatigue.
No fatigue-related claim appears in the provided label excerpts (indications, dosing modification tables, and 5.5/sections shown).
Contradictions
Important Omissions
The indication is limited to adult patients with metastatic NSCLC whose tumors are ALK- or ROS1-positive as detected by an FDA-approved test; the claims did not include the adult/metastatic/FDA-approved test detection wording.
Importance:
Moderate
Vision change monitoring in the label is recommended monthly during treatment, and pediatric/young adult (ALCL) and pediatric IMT require baseline and follow-up ophthalmologic exams at specified intervals; the claims did not reflect these specific monitoring requirements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No direct contraindication or dosing-amount errors are asserted. However, one adverse effect claim (fatigue) is unsupported by the provided excerpts and generalization of monitoring/indication criteria could reduce label-accuracy, which is a potential safety/quality concern.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Some claims are not explicitly supported by the provided label excerpts (fatigue; specific “targeted therapy designed to block cancer signaling” phrasing) and the label’s indication/monitoring specifics were omitted.
Suggested Improvement
Rephrase mechanism and adverse-effect claims to track label language (e.g., “inhibitor of receptor tyrosine kinases including ALK/ROS1” and label-described visual symptom/monitoring specifics) and qualify indications with “adult,” “metastatic,” and “FDA-approved test detection.”